CXCR2 and triple-negative breast carcinoma: The best-known CXCR2 antagonists include SB225002: (N-(2-hydroxy-4-nitrophenyl)-N’-(2-bromophenyl)urea) [45], which has shown activity against glioma [46], androgen-independent prostate cancer [47], cervical cancer [7], chronic myeloid leukemia (CML) [48], nasopharyngeal carcinoma [49], oral squamous cell carcinoma [50], triple negative breast cancer [51], ovarian cancer [52], and cholangiocellular carcinoma [53].